In the post-pandemic world, health care professionals and surgeons will increasingly turn to immersive technologies – augmented reality (AR), virtual reality (VR) and mixed reality (MR) – which open up new possibilities for learning, remote collaboration, enhanced performance and collecting data.
Future Of Surgery: Virtual Reality, Robotics And Collaboration
Immersive technologies are becoming a reality in the OR. In Vivo explores the future of surgery, profiling innovators of augmented reality technologies and exploring the promise and challenges surrounding robotic surgery as companies try to take technologies to the next level.
More from New Science
• By
Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.
• By
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
• By
Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.
More from In Vivo
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.